No quarterly revenue total was found in Sagimet Biosciences Inc.'s SEC filings.
Sagimet Biosciences Inc. (SGMT) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $257.6 million in cash and investments and $1.9 million in total debt.
Revenue
—
Net income
$-13.95M
-34.3% vs year-ago quarter
Operating cash flow
$-11.10M
-22.0% vs year-ago quarter
Free cash flow
—
EPS
$-0.26
+18.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
30.67M
+43.5% vs year-ago quarter
Net cash
$255.62M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SGMT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Foster City, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1400118
- Former names
- 3-V Biosciences, Inc. (until Feb 25, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$15.8M | -$11.7M | -$10.8M | -$14.3M | -$11.9M |
| Net income | -$14.0M | -$10.7M | -$9.6M | -$12.9M | -$10.4M |
| Diluted EPS | -$0.26 | -$0.33 | -$0.29 | -$0.40 | -$0.32 |
| Operating cash flow | -$11.1M | -$8.6M | -$11.8M | -$10.2M | -$9.1M |
| Total assets | $263.4M | $107.8M | $116.5M | $128.4M | $137.4M |
| Total liabilities | $7.3M | — | — | — | — |
| Stockholders' equity | $256.2M | $102.5M | $111.4M | $119.3M | $130.2M |
| Cash and investments | $257.6M | $104.5M | $113.1M | $125.5M | $135.5M |
| Total debt | $1.9M | $39,000 | $78,000 | $115,000 | $152,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 1, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
All 262 Sagimet Biosciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.